Filana Therapeutics, Inc. Payments to Acquire Marketable Securities
Filana Therapeutics, Inc. (FLNA) reported Payments to Acquire Marketable Securities of $399.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-29.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2019-03-29
- Filana Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- Filana Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- Filana Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2017-06-30 was $0.00.
- Filana Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2017-03-31 was $399.00K, a 73.35% decline year-over-year.
- Filana Therapeutics, Inc. payments to acquire marketable securities for fiscal 2017 was $399.00K, a 90.36% decline from fiscal 2016.
- Filana Therapeutics, Inc. payments to acquire marketable securities for fiscal 2016 was $4.14M, a 7.64% increase from fiscal 2015.
- Filana Therapeutics, Inc. payments to acquire marketable securities for fiscal 2015 was $3.85M, a 48.08% increase from fiscal 2014.
- Filana Therapeutics, Inc. payments to acquire marketable securities for fiscal 2014 was $2.60M, a 60.90% decline from fiscal 2013.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $0.00 derived: sum of 2 quarters · filed 2019-03-29 | $0.00 derived: sum of 3 quarters · filed 2019-03-29 | $399.00K 10-K · filed 2019-03-29 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30 | $0.00 derived: sum of 2 quarters · filed 2018-10-30 | $399.00K 10-Q · filed 2018-10-30 | $2.49M derived: sum of 4 quarters · filed 2018-10-30 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $399.00K 10-Q · filed 2018-07-26 | $2.49M derived: sum of 3 quarters · filed 2018-07-26 | $3.04M derived: sum of 4 quarters · filed 2018-07-26 |
| 2017-03-31 | $399.00K 10-Q · filed 2018-05-09 | $2.49M derived: sum of 2 quarters · filed 2018-05-09 | $3.04M derived: sum of 3 quarters · filed 2018-05-09 | $3.04M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-06 | $2.64M derived: sum of 2 quarters · filed 2018-02-06 | $2.64M derived: sum of 3 quarters · filed 2018-02-06 | $4.14M 10-K · filed 2018-02-06 |
| 2016-09-30 | $549.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $549.00K derived: sum of 2 quarters · filed 2017-11-01 | $2.05M 10-Q · filed 2017-11-01 | $2.05M derived: sum of 4 quarters · filed 2017-11-01 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $1.50M 10-Q · filed 2017-08-09 | $1.50M derived: sum of 3 quarters · filed 2017-08-09 | $2.40M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-03-31 | $1.50M 10-Q · filed 2017-04-26 | $1.50M derived: sum of 2 quarters · filed 2017-04-26 | $2.40M derived: sum of 3 quarters · filed 2017-04-26 | $3.35M derived: sum of 4 quarters · filed 2017-04-26 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | $899.00K derived: sum of 2 quarters · filed 2017-03-07 | $1.85M derived: sum of 3 quarters · filed 2017-03-07 | $3.85M 10-K · filed 2017-03-07 |
| 2015-09-30 | $899.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | $1.85M derived: sum of 2 quarters · filed 2016-10-26 | $3.85M 10-Q · filed 2016-10-26 | $3.85M derived: sum of 4 quarters · filed 2017-03-07 |
| 2015-06-30 | $949.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-19 | $2.95M 10-Q · filed 2016-07-19 | $2.95M derived: sum of 3 quarters · filed 2017-03-07 | $4.05M derived: sum of 4 quarters · filed 2017-03-07 |
| 2015-03-31 | $2.00M 10-Q · filed 2016-05-05 | $2.00M derived: sum of 2 quarters · filed 2017-03-07 | $3.10M derived: sum of 3 quarters · filed 2017-03-07 | $3.35M derived: sum of 4 quarters · filed 2017-03-07 |
| 2014-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | $1.10M derived: sum of 2 quarters · filed 2017-03-07 | $1.35M derived: sum of 3 quarters · filed 2017-03-07 | $2.60M 10-K · filed 2017-03-07 |
| 2014-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $1.35M derived: sum of 2 quarters · filed 2015-11-09 | $2.60M 10-Q · filed 2015-11-09 | $3.85M derived: sum of 4 quarters · filed 2016-03-03 |
| 2014-06-30 | $249.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-23 | $1.50M 10-Q · filed 2015-07-23 | $2.75M derived: sum of 3 quarters · filed 2016-03-03 | $4.05M derived: sum of 4 quarters · filed 2016-03-03 |
| 2014-03-31 | $1.25M 10-Q · filed 2015-05-08 | $2.50M derived: sum of 2 quarters · filed 2016-03-03 | $3.80M derived: sum of 3 quarters · filed 2016-03-03 | $5.10M derived: sum of 4 quarters · filed 2016-03-03 |
| 2013-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $2.55M derived: sum of 2 quarters · filed 2016-03-03 | $3.85M derived: sum of 3 quarters · filed 2016-03-03 | $6.64M 10-K · filed 2016-03-03 |
| 2013-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $2.60M derived: sum of 2 quarters · filed 2014-11-05 | $5.39M 10-Q · filed 2014-11-05 | $12.29M derived: sum of 4 quarters · filed 2015-02-18 |
| 2013-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | $4.10M 10-Q · filed 2014-08-06 | $10.99M derived: sum of 3 quarters · filed 2015-02-18 | $15.27M derived: sum of 4 quarters · filed 2015-02-18 |
| 2013-03-31 | $2.80M 10-Q · filed 2014-05-07 | $9.69M derived: sum of 2 quarters · filed 2015-02-18 | $13.97M derived: sum of 3 quarters · filed 2015-02-18 | $18.77M derived: sum of 4 quarters · filed 2015-02-18 |
| 2012-12-31 | $6.89M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-18 | $11.18M derived: sum of 2 quarters · filed 2015-02-18 | $15.97M derived: sum of 3 quarters · filed 2015-02-18 | $20.77M 10-K · filed 2015-02-18 |
| 2012-09-30 | $4.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-01 | $9.08M derived: sum of 2 quarters · filed 2013-11-01 | $13.88M 10-Q · filed 2013-11-01 | |
| 2012-06-30 | $4.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $9.59M 10-Q · filed 2013-08-01 | ||
| 2012-03-31 | $4.79M 10-Q · filed 2013-04-24 | |||
| 2011-12-31 | $2.50M 10-K · filed 2014-02-05 | |||
| 2010-12-31 | $14.99M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-08 | $33.90M derived: sum of 2 quarters · filed 2013-02-08 | $65.75M 10-K · filed 2013-02-08 | |
| 2010-09-30 | $18.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $50.77M 10-Q · filed 2011-11-03 | ||
| 2010-06-30 | $31.85M 10-Q · filed 2011-08-04 | |||
| 2009-12-31 | $154.00M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |